share_log

TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma

TCR2 Therapeutics Shares Jump After Additional Reponses in Ovarian Cancer, Mesothelioma

TCR2治療公司在卵巢癌和間皮瘤的額外治療後股價上漲
Benzinga Real-time News ·  2022/09/28 08:08
  • TCR2 Therapeutics Inc (NASDAQ:TCRR) has announced topline results from the Phase 1 portion of the gavo-cel Phase 1/2 trial for mesothelin-expressing solid tumors.
  • Gavo-cel demonstrated a disease control rate (DCR) of 77%. 28 of the 30 (93%) patients evaluable for efficacy experienced tumor regression of their target lesions, ranging in magnitude from 4% to 80%.
  • Eight patients experienced target lesion regression greater than 30%, six of whom achieved a partial response (PR).
  • One patient with cholangiocarcinoma was also considered to have achieved a PR, demonstrating that gavo-cel has induced responses in every tumor type tested.
  • The overall response rate (ORR) among patients who received gavo-cel following lymphodepletion chemotherapy was 22% by BICR and 26% by investigator assessment.
  • The median overall survival (OS) for patients with MPM was 11.2 months, whereas the median progression-free survival (PFS) for patients with MPM was 5.6 months.
  • Gavo-cel was generally well tolerated, with a manageable adverse event profile up to DL5.
  • Price Action: TCRR shares are up 9.47% at $1.85 during the premarket session on the last check Wednesday.
  • TCR2治療公司納斯達克公司(Temasek Holdings：TCRR)宣佈了Gavo-cel 1/2期實體腫瘤試驗的1期臨牀試驗的TOPLINE結果。
  • Gavo-cel疾病控制率(DCR)為77%。在可評估療效的30名患者中，有28名(93%)的靶病變腫瘤消退，幅度從4%到80%不等。
  • 8例靶病變消退超過30%，其中6例部分緩解(PR)。
  • 一名膽管細胞癌患者也被認為獲得了PR，這表明Gavo-cel在所測試的每一種腫瘤類型中都有誘導反應。
  • 在淋巴清除化療後接受Gavocel治療的患者中，BICR的總有效率(ORR)為22%，研究人員評估的總有效率(ORR)為26%。
  • 中位總生存期(OS)為11.2個月，中位無進展生存期(PFS)為5.6個月。
  • Gavo-cel總體耐受性良好，不良事件發生率可達DL5。
  • 價格行動：週三收盤前，TCRR股價上漲9.47%，至1.85美元。
声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論